AstraZeneca had partnered with Oxford University to develop the Covid-19 vaccine, which was sold in India as Covishield and as Vaxzevria in Europe.
AstraZeneca has begun the global withdrawal of its COVID-19 vaccine, Vaxzevria. This decision comes amid a surplus of more advanced vaccines targeting emerging variants of the virus.
The Gujarat Congress has urged for compensation for families affected by alleged Covishield-related deaths, citing neglect of WHO guidelines by the BJP-led central government. BJP-affiliated doctors deny a direct link between the vaccine and adverse events.
AstraZeneca restates dedication to patient safety and the safety profile of its COVID-19 vaccine amidst worries about rare side effects.
AstraZeneca's admission about the rare side effects of Covishield may have caused some concern among people. However, it is vital to remember that these are rare cases, and the benefits of getting vaccinated far outweigh any potential risks.
The Shanghai Public Health Clinical Center said that Zhang’s lab was informed about the move and added the lab was closed for “safety reasons.” However, the Chinese scientist refuted the government's claims and said he wasn't informed earlier.
AstraZeneca, the pharmaceutical company that produces Covid-19 vaccines such as Covishield, has acknowledged in a legal dispute that in extremely rare instances, their vaccine may cause serious side effects, including blood clots.
Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory said Bombay High Court.
SII Chief Executive Officer Adar Poonawalla said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.
At present, the gap between the second Covid jab and the precaution dose is nine months.
Serum Institute of India CEO Adar Poonawalla said that SII has decided to revise the price of Covishield vaccine for private hospitals after discussions with the Central government.
SII CEO Adar Poonawalla also welcomed the government’s move to allow precaution dose of the vaccine to all aged above 18 years at private vaccination centres, saying it will further provide long-term protection against the virus, and aid ease of travel.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
The DCGI approval came after the Subject Expert Committee (SEC) on COVID-19 recommended granting regular market approval to Covishield and Covaxin.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.
The BJP emerged as the single largest party bagging 384 seats against the MVA tally of 944 comprising Nationalist Congress Party's 344, Congress' 316 and Shiv Sena's 284 seats.
Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.
Stunned over the "miraculous recovery", a three-member medical team was constituted by the government to investigate the matter, doctors said.
DCGI has approved molnupiravir for the treatment of adult patients with Covid-19 who have high risk of progression of the disease including hospitalisation or death.
According to reports, Bharat Biotech has proposed that its nasal vaccine can be used as booster dose for those who have already been inoculated with Covaxin or Covishield vaccines against coronavirus.
Top News
Latest News
